Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) started the day on May 25, 2023, with a price decrease of -5.08% at $2.80. During the day, the stock rose to $3.0089 and sunk to $2.71 before settling in for the price of $2.95 at the close. Taking a more long-term approach, CRVS posted a 52-week range of $0.61-$3.70.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Meanwhile, its Annual Earning per share during the time was 20.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 14.10%. This publicly-traded company’s shares outstanding now amounts to $46.56 million, simultaneously with a float of $41.55 million. The organization now has a market capitalization sitting at $132.80 million. At the time of writing, stock’s 50-day Moving Average stood at $1.40, while the 200-day Moving Average is $1.00.
Corvus Pharmaceuticals Inc. (CRVS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Corvus Pharmaceuticals Inc.’s current insider ownership accounts for 0.10%, in contrast to 47.70% institutional ownership. According to the most recent insider trade that took place on May 15, this organization’s Director bought 10,000 shares at the rate of 2.45, making the entire transaction reach 24,500 in total value, affecting insider ownership by 10,000. Preceding that transaction, on Dec 20, Company’s official bought 20,000 for 0.79, making the whole transaction’s value amount to 15,800. This particular insider is now the holder of 133,773 in total.
Corvus Pharmaceuticals Inc. (CRVS) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 3/30/2023, the organization reported -$0.17 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.16) by -$0.01. This company achieved a return on equity of -53.90. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
Corvus Pharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 14.10% and is forecasted to reach -0.41 in the upcoming year.
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) Trading Performance Indicators
Let’s observe the current performance indicators for Corvus Pharmaceuticals Inc. (CRVS). It’s Quick Ratio in the last reported quarter now stands at 4.30. The Stock has managed to achieve an average true range (ATR) of 0.35.
In the same vein, CRVS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.88, a figure that is expected to reach -0.12 in the next quarter, and analysts are predicting that it will be -0.41 at the market close of one year from today.
Technical Analysis of Corvus Pharmaceuticals Inc. (CRVS)
If we take a close look at the recent performances of Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), its last 5-days Average volume was 1.09 million that shows progress from its year to date volume of 0.51 million. During the previous 9 days, stock’s Stochastic %D was recorded 57.04% While, its Average True Range was 0.40.
Raw Stochastic average of Corvus Pharmaceuticals Inc. (CRVS) in the period of the previous 100 days is set at 70.90%, which indicates a major rise in contrast to 64.29% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 204.63% that was higher than 112.16% volatility it exhibited in the past 100-days period.